Natera has expanded its Fetal Focus single‑gene non‑invasive prenatal test (NIPT) panel from 5 to 20 genes, with the new panel scheduled to launch in the fourth quarter of 2025.
The expansion leverages Natera’s proprietary LinkedSNP technology, which improves detection of inherited conditions across a broader gene set and has already identified a cystic fibrosis case missed by another laboratory.
The initial 5‑gene Fetal Focus test was launched in August 2025, and the 20‑gene panel will provide parents with a more comprehensive assessment of fetal health from a single, non‑invasive blood draw.
Natera’s Q4 2024 revenue reached $476.1 million, a 53% year‑over‑year increase from $311.1 million in Q4 2023, and its gross margin rose to 62.9% from 51.4% in the prior year. Full‑year 2024 revenue was $1.696 billion, up 56.7% from $1.083 billion in 2023.
The company projects 2025 total revenue between $1.87 billion and $1.95 billion, driven in part by the expanded prenatal portfolio and strong growth in oncology test volumes, which reached 151,000 in Q4 2024, up 55% YoY.
Natera’s expansion into 20 genes positions it to capture a larger share of the growing single‑gene NIPT market, competing with players such as Illumina, Ariosa Diagnostics, and Sequenom. The company’s LinkedSNP technology is a key differentiator, particularly for detecting challenging homozygous cases.
The 20‑gene panel is expected to increase test volumes and contribute to revenue growth in the women’s health segment, reinforcing Natera’s broader strategy to broaden its prenatal portfolio and strengthen its competitive edge in precision diagnostics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.